Valuation: Mylan N.V.

Market Cap 20.03B 18.01B 16.81B 15.23B 28.6B 1,906B 28.78B 202B 78.76B 989B 75.21B 73.58B 3,182B P/E 2026 *
75.7x
P/E 2027 * 46.6x
Enterprise Value 31.98B 28.76B 26.83B 24.32B 45.66B 3,044B 45.95B 322B 126B 1,580B 120B 117B 5,080B EV / Sales 2026 *
2.16x
EV / Sales 2027 * 2.04x
Free-Float
91.44%
Yield 2026 *
2.92%
Yield 2027 * 2.99%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 20.03B
+3.62%+1.68%+48.80%+98.41% 1,077B
+2.13%-1.76%+33.04%+61.88% 612B
+3.32%+4.47%+23.72%+91.59% 501B
+3.80%+3.21%+73.99%+41.69% 364B
+1.21%+6.72%+32.49%+49.28% 353B
+1.60%+5.86%+19.78%+42.91% 278B
+2.95%+6.31%-0.02%+15.22% 251B
+3.21%+3.15%+45.01%+49.99% 230B
+3.80%+4.56%+29.59%+97.73% 190B
Average +1.74%+1.97%+34.04%+60.97% 428.5B
Weighted average by Cap. +1.56%+1.58%+37.48%+69.55%

Financials

2026 *2027 *
Net sales 14.79B 13.3B 12.41B 11.25B 21.12B 1,408B 21.25B 149B 58.16B 731B 55.53B 54.33B 2,350B 15.04B 13.52B 12.62B 11.44B 21.47B 1,431B 21.61B 151B 59.13B 743B 56.47B 55.24B 2,389B
Net income 142M 127M 119M 108M 202M 13.47B 203M 1.43B 556M 6.99B 531M 520M 22.48B 298M 268M 250M 227M 426M 28.4B 429M 3B 1.17B 14.74B 1.12B 1.1B 47.4B
Net Debt 11.95B 10.74B 10.03B 9.09B 17.06B 1,137B 17.17B 120B 46.99B 590B 44.87B 43.9B 1,898B 10.68B 9.61B 8.96B 8.12B 15.25B 1,017B 15.35B 108B 42.01B 528B 40.11B 39.24B 1,697B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Mylan N.V.